qbw251
Small moleculeexperimental
Clinical trial activity
13 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
8
Phase 3
3
Phase 4
0
Earliest trial started Jul 1, 2012 (NCT02190604)
Timeline
Indications
Mechanism of action
CFTR activator
Indication: Cystic Fibrosis, COPD
Chemistry & pharmacology
Loading structure…
SMILES
COc1nc(C(=O)NC[C@](C)(O)C(F)(F)F)c(N)cc1C(F)(F)F- Mol. weight
- 361.24 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650318 ↗
- ChEMBLCHEMBL3545292 ↗
Also known as
- qbw251
- qbw251
- qbw-251
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06259526 | Phase 2 | Dec 26, 2023 | Tasly Pharmaceuticals, Inc. |
| NCT06125327 | Phase 2/Phase 3 (Phase 3) | Jun 6, 2023 | Government of China |
| NCT07030504 | Phase 1 | Jan 10, 2023 | Shenzhen Salubris Pharmaceuticals Co., Ltd., Shenzhen University |
| NCT06135363 | Phase 1 | Aug 11, 2022 | Government of China |
| NCT05604170 | Phase 3 | May 16, 2022 | Marinus Pharmaceuticals |
| NCT05323734 | Phase 3 | Apr 1, 2022 | Marinus Pharmaceuticals |
| NCT06160440 | Phase 1 | Jun 3, 2021 | Government of China |
| NCT04396366 | Phase 2 | Nov 30, 2020 | European Commission, Novartis |
| NCT04587622 | Phase 1 | Oct 30, 2020 | Novartis |
| NCT04268823 | Phase 2 | Mar 23, 2020 | Novartis |
| NCT04072887 | Phase 2 | Sep 23, 2019 | Novartis |
| NCT02449018 | Phase 2 | Apr 1, 2015 | Novartis |
| NCT02190604 | Phase 2 | Jul 1, 2012 | Novartis |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 6 | 6 | 2 | 2012 |
| Government of China | Government | 3 | 3 | 2 | 2021 |
| Marinus Pharmaceuticals | For profit | 2 | 2 | 1 | 2022 |
| European Commission | Government | 1 | 0 | 1 | 2020 |
| Shenzhen Salubris Pharmaceuticals Co., Ltd. | For profit | 1 | 1 | 1 | 2023 |
| Shenzhen University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Tasly Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2023 |
7 organizations
Page 1 / 1